이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Charles River Laboratories International 과거 수익 실적
과거 기준 확인 2/6
Charles River Laboratories International은 연평균 16%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 16.8%였습니다. 매출은 연평균 12.2%의 비율로 증가했습니다. Charles River Laboratories International의 자기자본이익률은 12.2%이고 순이익률은 10.8%입니다.
주요 정보
16.0%
수익 성장률
14.8%
EPS 성장률
Life Sciences 산업 성장 | 21.5% |
매출 성장률 | 12.2% |
자기자본 수익률 | 12.2% |
순이익 | 10.8% |
최근 수익 업데이트 | 30 Mar 2024 |
최근 과거 실적 업데이트
Recent updates
Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14수익 및 비용 분석
수익 및 비용 분석
Charles River Laboratories International 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Mar 24 | 4,112 | 444 | 739 | 0 |
30 Dec 23 | 4,129 | 475 | 736 | 0 |
30 Sep 23 | 4,216 | 475 | 752 | 0 |
01 Jul 23 | 4,178 | 484 | 757 | 0 |
01 Apr 23 | 4,092 | 496 | 685 | 0 |
31 Dec 22 | 3,976 | 486 | 655 | 0 |
24 Sep 22 | 3,781 | 436 | 585 | 0 |
25 Jun 22 | 3,688 | 443 | 549 | 0 |
26 Mar 22 | 3,630 | 422 | 578 | 0 |
25 Dec 21 | 3,540 | 391 | 578 | 0 |
25 Sep 21 | 3,426 | 397 | 582 | 0 |
26 Jun 21 | 3,273 | 396 | 566 | 0 |
27 Mar 21 | 3,041 | 375 | 528 | 0 |
26 Dec 20 | 2,924 | 364 | 523 | 0 |
26 Sep 20 | 2,824 | 301 | 501 | 0 |
27 Jun 20 | 2,749 | 271 | 502 | 0 |
28 Mar 20 | 2,724 | 248 | 520 | 0 |
28 Dec 19 | 2,621 | 252 | 488 | 0 |
28 Sep 19 | 2,532 | 231 | 493 | 0 |
29 Jun 19 | 2,449 | 219 | 473 | 0 |
30 Mar 19 | 2,377 | 227 | 456 | 0 |
29 Dec 18 | 2,266 | 225 | 436 | 0 |
29 Sep 18 | 2,143 | 135 | 419 | 0 |
30 Jun 18 | 2,022 | 128 | 401 | 0 |
31 Mar 18 | 1,906 | 129 | 377 | 0 |
30 Dec 17 | 1,858 | 123 | 367 | 0 |
30 Sep 17 | 1,846 | 198 | 370 | 0 |
01 Jul 17 | 1,807 | 183 | 363 | 0 |
01 Apr 17 | 1,772 | 164 | 357 | 0 |
31 Dec 16 | 1,681 | 154 | 343 | 0 |
24 Sep 16 | 1,568 | 143 | 325 | 0 |
25 Jun 16 | 1,492 | 143 | 309 | 0 |
26 Mar 16 | 1,398 | 156 | 288 | 0 |
26 Dec 15 | 1,363 | 150 | 279 | 0 |
26 Sep 15 | 1,339 | 146 | 277 | 0 |
27 Jun 15 | 1,317 | 140 | 276 | 0 |
28 Mar 15 | 1,319 | 127 | 274 | 0 |
27 Dec 14 | 1,298 | 128 | 258 | 0 |
27 Sep 14 | 1,257 | 120 | 248 | 0 |
28 Jun 14 | 1,222 | 119 | 236 | 0 |
29 Mar 14 | 1,174 | 111 | 226 | 0 |
28 Dec 13 | 1,166 | 104 | 226 | 0 |
28 Sep 13 | 1,156 | 108 | 213 | 0 |
29 Jun 13 | 1,143 | 99 | 210 | 0 |
양질의 수익: CRL 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: CRL 의 현재 순이익 이익률 (10.8%) 작년보다 낮습니다 (12.1%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: CRL 의 수입은 지난 5년 동안 매년 16% 씩 증가했습니다.
성장 가속화: CRL 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: CRL 은 지난 1년 동안 마이너스 수익 성장( -10.4% )을 기록하여 Life Sciences 업계 평균( -6.5% ).
자기자본 수익률
높은 ROE: CRL 의 자본 수익률( 12.2% )은 낮음으로 간주됩니다.